Related Experiment Video
Updated: Oct 24, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Emerging Treatment Strategies in Pancreatic Cancer
Andrew Trunk1, Laura Miotke1, Christopher Nevala-Plagemann2
1From the Department of Internal Medicine, University of Utah.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is one of the main causes of cancer death in well-developed countries. Therapeutic advances in PDAC to date have been modest. Recent progress to understand the molecular landscape of the disease has opened new treatment opportunities for a small subset of patients, frequently those with KRAS wild-type disease. Novel treatment strategies in PDAC include, among others, the use of nanotechnology and metabolic reprogramming. In addition, new strategies are being investigated, which are designed to overcome the resistance to checkpoint inhibitors, targeting DNA repair pathways including mismatch repair, increasing antigen presentation through the use of vaccines, targeting various signaling pathways, and reprogramming the tumor microenvironment. Here, we review the landscape of PDAC treatment strategies and some of these new agents.
Insights
Pancreatic ductal adenocarcinoma (PDAC) treatment is improving with new strategies like nanotechnology and metabolic reprogramming. Research is exploring ways to overcome resistance to checkpoint inhibitors and target tumor microenvironments for better outcomes.
Area of Science:
- Oncology
- Cancer Research
- Translational Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer mortality globally.
- Current therapeutic advances for PDAC have been limited.
- Molecular profiling has identified new treatment avenues, particularly for KRAS wild-type PDAC.
Purpose of the Study:
- To review the current landscape of pancreatic ductal adenocarcinoma treatment strategies.
- To highlight emerging therapeutic agents and novel approaches in PDAC management.
Main Methods:
- Literature review of recent advancements in PDAC treatment.
- Analysis of novel therapeutic strategies including nanotechnology, metabolic reprogramming, and immunotherapy resistance mechanisms.
Main Results:
- Progress in understanding PDAC molecular landscape offers targeted opportunities.
- Emerging strategies focus on overcoming immunotherapy resistance, DNA repair, antigen presentation, and tumor microenvironment modulation.
- Nanotechnology and metabolic reprogramming represent promising novel treatment avenues.
Conclusions:
- Despite modest historical advances, PDAC treatment is evolving with new molecular insights.
- Investigational strategies hold potential for improving outcomes in pancreatic cancer.
- A multifaceted approach targeting various pathways and the tumor microenvironment is crucial for future PDAC therapy.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...